NEW

Philips to Acquire Capsule Technologies Inc.

Royal Philips has signed an agreement to acquire Capsule Technologies Inc., a provider of medical device integration and data technologies for hospitals and healthcare organizations.

Camber Spine Expands Patent Portfolio with SPIRA Lateral 3.0

Camber Spine has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for its SPIRA Lateral 3.0 interbody fusion implant.

UVDI-360 Room Sanitizer Inactivates SARS-CoV-2 at 12 Feet Distance in 5 Minutes

UltraViolet Devices Inc. (UVDI) has announced that its UVDI-360 Room Sanitizer achieved greater than 99.99%, or 4log10, inactivation of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) in 5 minutes at a distance of 12 feet (3.65 meters).

oneSOURCE Creates Free Resource Page with Up-to-Date COVID-19 Vaccine Information

Today, oneSOURCE, an RLDatix company and leading healthcare management solution, announced a new COVID-19 vaccine resource page to assist healthcare professionals during the initial administration phases of the vaccine.

O2 RegenTech Receives $600,000 to Develop Oxygenating Wound Treatments

O2 RegenTech, a medical technology company focused on wound care solutions, has been awarded a $225,000 National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant to conduct research and development on its oxygenating wound dressing that enhances chronic wound healing. Additionally, the company received a $225,000 National Institutes of Health (NIH) Small Business Technology Transfer (STTR) grant and $150,000 from the Ohio Third Frontier (OTF) Technology Validation and Startup Fund (TVSF).

The three most important factors in wound healing are oxygen, moisture, and protection from bacteria to prevent infections. Currently, there are no wound treatments available that offer all three components at once, requiring patients to use a combination of different bandages, dressings, ointments, and other treatments. O2 RegenTech aims to make wound care simpler with its proprietary product, OXAID™, a treatment that provides all three important components to promote wound healing in one easy-to-use dressing.

“O2 RegenTech is extremely excited to receive the support of the NSF, the NIH, and the OTF,” said Dr. Andreas Inmann, President & CEO of O2 RegenTech. “This funding validates our approach and will be instrumental in moving our technology closer to regulatory submission and commercialization.”

Previous

Next

Submit a Comment

Your email address will not be published. Required fields are marked *

X